INGELHEIM, Germany I, 2025 I Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)∗ and OXB,ŧ today announce the start ...

A Charleston-area roofing company is officially being ejected from its workspace amid complaints that it took hundreds of ...

Hundreds of Lowcountry moms danced the night away all in support of research to support a treatment for a genetic disorder.

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started, either. Here are two no-brainer healthcare stocks to buy with $500 right ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

The technology, which can dramatically improve access to medicine, has already proved itself. America’s policies are lagging behind.

On the morning of Feb. 20, 2025, Auburn Mayor Ron Anders gave a proclamation at the Jay and Susie Gogue Performing Arts ...

NARBERTH, Pennsylvania (WPVI) -- "Take A Breather Foundation" based in Narberth is a stress relief outlet for people with cystic fibrosis. Their focus is to provide a "breather" to their recipients, ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.